BDB001-101: Clinical Study of BDB001 as a Mono-therapy or in Combination With Pembrolizumab
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03486301 |
|
Recruitment Status :
Active, not recruiting
First Posted : April 3, 2018
Last Update Posted : December 1, 2021
|
Sponsor:
Birdie Biopharmaceuticals HK Limited
Collaborator:
Seven and Eight Biopharmaceuticals Inc
Information provided by (Responsible Party):
Birdie Biopharmaceuticals HK Limited
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Active, not recruiting |
|---|---|
| Estimated Primary Completion Date : | December 2022 |
| Estimated Study Completion Date : | December 2022 |